Upload
quamar-phillips
View
14
Download
0
Embed Size (px)
DESCRIPTION
Group 4. Gaps & obstacles Priorities & Solutions. Key Issues. Ideal paediatric regimens Dosing & pharmacokinetics Programmatic evaluation. Ideal paediatric regimens. FDC-based Clinical & pK evaluation Can start with adult formulations Rapid development of paediatric formulations - PowerPoint PPT Presentation
Citation preview
Group 4
Gaps & obstacles
Priorities & Solutions
Key Issues
• Ideal paediatric regimens
• Dosing & pharmacokinetics
• Programmatic evaluation
Ideal paediatric regimens
• FDC-based– Clinical & pK evaluation
• Can start with adult formulations
• Rapid development of paediatric formulations
– NVP-exposed infants (& mothers) – develop a strategy now
• ?4drugs
• ABC & TFV
• More work on PI’s
• D4T endgame? – long term toxicity?
Dosing & Pharmacokinetics
• Rifampicin – NVP/EFV interactions• EFV <3y/10kg• X1 daily dosing regimens
– Incl 3TC, ddI, EFV, D4T, NVP, TFV
• Validating weight-band based tables – At extremes of bands– Efficacy & toxicity
• Dose clarification 3TC & NVP & ZDV
Programmatic:Longitudinal outcome cohorts
in resource-constrained settings
• Model program definition (for replication)– Decentralized– Nurse-managed– Community & family based with good referral network– Chronic care
• Systems for surveillance– Clinical outcome (incl drop-out rate)– Resistance– Toxicity
• Program evaluation– Forecasting evaluation
Who should do & who should fund?
• Should WHO, UNICEF, UNAID & partners co-ordinate process?
• Support from Regulatory authorities• National programs must endorse & support
appropriate research• Funding - PEPFAR, GATES, USAID, Research
networks, Academic institutions• Manufacturers (Innovator & Generic)• NGO – MSF, others
Other priorities
• Early diagnosis– Virological– Clinical
• Improved PMTCT interventions• Training & guidelines• Strategies
– When to start ART?– Can ART be stopped? CD4 guided STI